PacBio Announces SPRQ Chemistry for Revio Sequencing Systems, a Major Advance Reducing the Cost of a HiFi Human Genome to less than $500
PacBio has announced SPRQ, a new sequencing chemistry for its Revio long-read sequencing system that brings significant improvements. The update reduces DNA input requirements by 4x to 500ng per sample and increases data output by 33% per SMRT Cell. These enhancements enable sequencing costs to drop below $500 per human genome, with each Revio system capable of sequencing up to 2,500 human genomes annually. The upgrade also improves methylation calling accuracy and adds new methylation mark detection capabilities, providing enhanced multiomic analysis. The SPRQ chemistry will be compatible with all existing Revio systems through a simple software update, with shipping beginning in December 2024.
PacBio ha annunciato SPRQ, una nuova chimica di sequenziamento per il suo sistema di sequenziamento a lettura lunga Revio che porta miglioramenti significativi. L'aggiornamento riduce i requisiti di input di DNA di 4 volte a 500ng per campione e aumenta la produzione di dati di 33% per Cellula SMRT. Questi miglioramenti consentono ai costi di sequenziamento di scendere al di sotto di $500 per genoma umano, con ciascun sistema Revio capace di sequenziare fino a 2.500 genomi umani annualmente. L'upgrade migliora anche l'accuratezza della chiamata di metilazione e aggiunge nuove capacità di rilevamento dei segni di metilazione, fornendo un'analisi multiomica potenziata. La chimica SPRQ sarà compatibile con tutti i sistemi Revio esistenti tramite un semplice aggiornamento software, con le spedizioni che inizieranno a dicembre 2024.
PacBio ha anunciado SPRQ, una nueva química de secuenciación para su sistema de secuenciación de lectura larga Revio que trae mejoras significativas. La actualización reduce los requisitos de entrada de ADN a 4x a 500ng por muestra y aumenta la producción de datos en un 33% por Celda SMRT. Estas mejoras permiten que los costos de secuenciación caigan por debajo de $500 por genoma humano, con cada sistema Revio capaz de secuenciar hasta 2.500 genomas humanos anualmente. La actualización también mejora la precisión en la llamada de metilación y agrega nuevas capacidades de detección de marcas de metilación, proporcionando un análisis multiómico mejorado. La química SPRQ será compatible con todos los sistemas Revio existentes a través de una simple actualización de software, con envíos que comenzarán en diciembre de 2024.
PacBio는 Revio 장기 읽기 시퀀싱 시스템을 위한 새로운 시퀀싱 화학물질 SPRQ를 발표하며, 이로 인해 상당한 개선이 이루어졌습니다. 업데이트는 샘플당 DNA 입력 요구 사항을 4배로 줄여 500ng으로 감소시키고, SMRT 셀당 데이터 출력을 33% 증가시킵니다. 이러한 개선 사항은 시퀀싱 비용을 500달러 이하의 인간 유전체로 떨어뜨릴 수 있으며, 각 Revio 시스템은 연간 최대 2,500개의 인간 유전체를 시퀀싱할 수 있습니다. 업그레이드는 메틸화 호출 정확성을 개선하고 새로운 메틸화 마크 탐지 기능을 추가하여 다중 오믹 분석을 향상시킵니다. SPRQ 화학물질은 간단한 소프트웨어 업데이트를 통해 모든 기존 Revio 시스템과 호환되며, 2024년 12월에 배송이 시작될 예정입니다.
PacBio a annoncé SPRQ, une nouvelle chimie de séquençage pour son système de séquençage à long reads Revio, qui apporte des améliorations significatives. La mise à jour réduit les besoins en ADN à 4x 500ng par échantillon et augmente la production de données de 33% par Cellule SMRT. Ces améliorations permettent aux coûts de séquençage de descendre en dessous de 500 $ par génome humain, chaque système Revio étant capable de séquencer jusqu'à 2 500 génomes humains par an. L'upgrade améliore également la précision des appels de méthylation et ajoute de nouvelles capacités de détection des marques de méthylation, offrant ainsi une analyse multiomique améliorée. La chimie SPRQ sera compatible avec tous les systèmes Revio existants grâce à une simple mise à jour logicielle, avec un début des expéditions en décembre 2024.
PacBio hat SPRQ angekündigt, eine neue Sequenzierungschemie für sein Revio-System zur Langzeit-Sequenzierung, die wesentliche Verbesserungen mit sich bringt. Das Update reduziert die Anforderungen an die DNA-Eingabe auf 4x bis 500ng pro Probe und erhöht die Datenausgabe um 33% pro SMRT-Zelle. Diese Verbesserungen ermöglichen es den Sequenzierungskosten, unter 500 $ pro menschliches Genom zu fallen, wobei jedes Revio-System in der Lage ist, jährlich bis zu 2.500 menschliche Genome zu sequenzieren. Das Upgrade verbessert auch die Genauigkeit der Methylierungserkennung und fügt neue Erkennungsfunktionen für Methylierungsmarken hinzu, die eine verbesserte multiomische Analyse bieten. Die SPRQ-Chemie wird durch ein einfaches Software-Update mit allen bestehenden Revio-Systemen kompatibel sein, wobei der Versand im Dezember 2024 beginnt.
- Reduces DNA input requirements by 4x to 500ng per sample
- Increases sequencing yield by 33% per SMRT Cell
- Reduces sequencing cost per genome by up to 50%
- Enables processing of up to 2,500 human genomes per year per instrument
- Improves methylation calling accuracy
- None.
Insights
This breakthrough in sequencing chemistry represents a significant technological and commercial advancement. The 4x reduction in DNA input requirements to 500ng and 33% increase in sequencing yield per SMRT Cell dramatically expands market accessibility. The ability to sequence up to 2,500 human genomes annually at
The improved methylation detection capabilities and multiomics support position PacBio more competitively against short-read alternatives. The compatibility with existing Revio systems through a simple software update ensures rapid market implementation without requiring new capital investment from current customers. This could drive both increased utilization of installed systems and new system sales.
The reduction in cost per genome to under
The timing of this announcement ahead of the ASHG conference, a major industry event, maximizes visibility and potential customer engagement. With immediate ordering availability and December shipping, this could positively impact Q4 2024 revenues and 2025 projections.
New long-read sequencing chemistry reduces DNA input requirements four-fold, enables a
MENLO PARK, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced SPRQ, an improved sequencing chemistry for its Revio™ long-read sequencing system. The new chemistry will reduce Revio DNA input requirements by 4x to 500ng per sample, which enables more sample types such as saliva extracted with PacBio’s new Nanobind protocol and tumor samples to be sequenced with HiFi sequencing technology. It will also increase the Revio system’s output, which together with improved analysis methods, enables customers to reduce their sequencing cost per genome by up to 50 percent. Paired instrument software enhancements will also improve the accuracy of methylation calling and add detection of new types of methylation marks providing customers with a rich, multiomic view of every sample.
“We’ve seen tremendous demand for Revio systems over the last two years as many more researchers have discovered the superiority of HiFi technology in population sequencing and other human and non-human sequencing applications,” said Christian Henry, President and Chief Executive Officer of PacBio. “Our team has achieved significant breakthroughs which significantly improves the performance and reduces the cost of a HiFi human genome to less than
The SPRQ chemistry will increase the efficiency of loading on Revio SMRT Cells, reducing DNA input requirements to just 500 ng, a four-fold reduction. The chemistry will also improve sequencing performance, providing a
"Increased yields and reduced input requirements are a big win for our user community,” said Niall Lennon, Chair and Chief Scientific Officer of Broad Clinical Labs. “In studies where we had many samples that we could not have generated long reads on before, we were able to rescue
In addition, a SMRT Link and instrument software upgrade paired with the release of SPRQ chemistry provides new DNA methylation callers that greatly increase the multiomics capabilities of every Revio run. The software brings improved accuracy for calling 5mC, making HiFi sequencing an attractive alternative to methylation arrays. It also adds a new capability to call 6mA, which is used as a marker of open chromatin in the Fiber-seq assay, providing DNA, methylation, and chromatin accessibility all from a single DNA input and sequencing run.
"Our lab’s Fiber-seq assay adds chromatin accessibility to the multiomic view of a genome provided by HiFi sequencing. Fiber-seq is seeing growing use in pangenome research, rare disease research, and in the study of somatic variation. We are excited to see an accurate 6mA caller on the Revio system to simplify the computational analysis of Fiber-seq chromatin stencils and support further adoption,” said Andrew Stergachis, MD, PhD, Associate Professor, Medical Genetics at University of Washington.
PacBio will present data on the new SPRQ chemistry at a workshop at the American Society of Human Genetics annual meeting taking place in Denver, Colorado, November 5-9, 2024. The workshop on November 8, 2024 from 12:00-1:00 p.m. MST in rooms 109-111-113, “A new era in rare disease research: integrating HiFi sequencing into clinical practice and population genomics,” will feature speakers including David Miller, Vice President Global Marketing at PacBio, Michael Eberle, Ph.D., Vice President Computational Biology at PacBio, Carol Saunders, Ph.D., FACMG, Division Director, Clinical & Laboratory Genetics & Genomics, Children’s Mercy Kansas City, and Mait Metspalu, Ph.D., Director, Institute of Genomics, Estonian Biocentre. The company will also be exhibiting all week at booth #725.
The SPRQ chemistry and SMRT Link software are available for order starting immediately and will begin shipping in December 2024. To learn more visit https://programs.pacb.com/ashg2024.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Forward-Looking Statements:
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the expected release date, uses, coverage, advantages, or quality or performance of, or benefits or expected benefits of using, PacBio products or technologies, such as expected release date of SPRQ, anticipated reductions in DNA input requirements and the cost of a HiFi genome to less than
Contacts
For investors:
Todd Friedman
IR@pacificbiosciences.com
For media:
PR@pacificbiosciences.com
FAQ
What is the cost per human genome with PacBio's new SPRQ chemistry?
When will PacBio (PACB) begin shipping the new SPRQ chemistry?
How much does the SPRQ chemistry reduce DNA input requirements for PacBio Revio systems?
What is the increase in sequencing yield with PacBio's SPRQ chemistry?
